PMID- 11334727
OWN - NLM
STAT- MEDLINE
DCOM- 20010628
LR  - 20190718
IS  - 0959-8049 (Print)
IS  - 0959-8049 (Linking)
VI  - 37
IP  - 8
DP  - 2001 May
TI  - Antitumour activity of somatostatin analogues in progressive metastatic 
      neuroendocrine tumours.
PG  - 1014-9
AB  - A few studies have suggested an antitumour activity of somatostatin analogues in 
      neuroendocrine tumours (NET). The aim of this study was to evaluate the 
      antitumour efficacy of somatostatin analogues in patients with documented 
      progressive tumours. 35 consecutive patients with documented tumour progression 
      were treated with somatostatin analogues. Patients were classified into two 
      groups. In Group 1, tumours were progressing rapidly (an increase of 50% or more 
      in the lesion surface area in 3 months) and in Group 2, tumours were progressing 
      more slowly (an increase of less than 50% in the lesion surface area in 3 months 
      but greater than 25% in 6 months). Treatment consisted of subcutaneous (s.c.) 
      octreotide, 100 microg thrice daily for 17 patients, intramuscular lanreotide, 30 
      mg/every 14 days for 11 patients and for 7 patients both somatostatin analogues 
      were used successively during the follow-up. Primary tumour sites were the small 
      intestine (n=12), pancreas (n=13), lungs (n=5), and other sites (n=5). 18 
      patients had the carcinoid syndrome with flushing and/or diarrhoea. The median 
      duration of treatment was 7 months. Treatment was discontinued in 3 patients due 
      to side-effects. One patient (3%) achieved a partial response and the disease was 
      stabilised in 20 patients (57%) for a median duration of 11 months (6-48 months). 
      Stabilisation of patients in Group 1 was significantly less frequent at 6 months 
      than that of patients in Group 2 (4/12 and 13/17 respectively, P<0.02). 
      Somatostatin analogue treatment resulted in one partial response (3%) and 20 
      cases of stabilisation (57%) in 35 patients with progressive NET. A slow tumour 
      growth rate before treatment is predictive of a good response to somatostatin 
      analogues which could be considered an option for first-line treatment.
FAU - Aparicio, T
AU  - Aparicio T
AD  - Service de Gastroenterologie, Institut Gustave Roussy, 94805, Villejuif, France.
FAU - Ducreux, M
AU  - Ducreux M
FAU - Baudin, E
AU  - Baudin E
FAU - Sabourin, J C
AU  - Sabourin JC
FAU - De Baere, T
AU  - De Baere T
FAU - Mitry, E
AU  - Mitry E
FAU - Schlumberger, M
AU  - Schlumberger M
FAU - Rougier, P
AU  - Rougier P
LA  - eng
PT  - Journal Article
PL  - England
TA  - Eur J Cancer
JT  - European journal of cancer (Oxford, England : 1990)
JID - 9005373
RN  - 0 (Antineoplastic Agents, Hormonal)
RN  - 0 (Peptides, Cyclic)
RN  - 0G3DE8943Y (lanreotide)
RN  - 51110-01-1 (Somatostatin)
RN  - RWM8CCW8GP (Octreotide)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents, Hormonal/*therapeutic use
MH  - Disease Progression
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neuroendocrine Tumors/*drug therapy
MH  - Octreotide/*therapeutic use
MH  - Peptides, Cyclic/*therapeutic use
MH  - Somatostatin/*analogs & derivatives/*therapeutic use
MH  - Treatment Outcome
EDAT- 2001/05/04 10:00
MHDA- 2001/06/29 10:01
CRDT- 2001/05/04 10:00
PHST- 2001/05/04 10:00 [pubmed]
PHST- 2001/06/29 10:01 [medline]
PHST- 2001/05/04 10:00 [entrez]
AID - S0959804901000739 [pii]
AID - 10.1016/s0959-8049(01)00073-9 [doi]
PST - ppublish
SO  - Eur J Cancer. 2001 May;37(8):1014-9. doi: 10.1016/s0959-8049(01)00073-9.